Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance

被引:81
作者
Vermeeren, A [1 ]
O'Hanlon, JF [1 ]
机构
[1] Maastricht Univ, Dept Biol Psychol, Inst Human Psychopharmacol, NL-6200 MD Maastricht, Netherlands
关键词
fexofenadine; clemastine; antihistamines; alcohol interactions; healthy volunteers; car driving; psychomotor performance;
D O I
10.1016/S0091-6749(98)70240-4
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Fexofenadine is the hydrochloride salt of terfenadine's active metabolite. Objective: Fexofenadine's effects on performance were assessed in this study for the purpose of determining its safety of use by patients wire engage in potentially dangerous activities, especially car driving. Methods: Fexofenadine was administered in daily doses of 120 or 240 mg, each in single and divided units given over 5 days. Two milligrams of clemastine given twice daily and placebo were given in similar series. Twenty-Four healthy volunteers (12 men, 12 women; age range, 21 to 45 years) participated in a double-blind six-way crossover study. Psychomotor tests (critical tracking, choice reaction time, and sustained attention) and a standardized actual driving test were undertaken between 1.5 to 4 hours after administration of the morning dose on days I, 4, and 5 of each series. On day 5, subjects were challenged with a moderate alcohol dose before testing. Results: Fexofenadine did not impair driving performance. On the contrary, driving performance was consistently better during twice daily treatment with 120 mg fexofenadine than during treatment with placebo, significantly so on day 4. Both of the 240 mg/day regimens significantly attenuated alcohol's adverse effect: on driving on dag 5, Effects in psychomotor tests acre mot significant, with the exception of the critical tracking test in which the first single doses of fexofenadine, 120 and 240 mg. had significantly impairing effects. Conclusion: It was concluded that fexofenadine has no effect ore performance after being taken in the recommended dosage of 60 mg twice daily.
引用
收藏
页码:306 / 311
页数:6
相关论文
共 28 条
[1]  
Bernstein D., 1996, Journal of Allergy and Clinical Immunology, V97, P435, DOI 10.1016/S0091-6749(96)81228-0
[2]  
BETTS T, 1989, J PSYCHOPHARMACOL, V3, P101
[3]   ACUTE AND SUBCHRONIC EFFECTS OF THE H-1-HISTAMINE RECEPTOR ANTAGONIST EBASTINE IN 10, 20 AND 30 MG DOSE, AND TRIPROLIDINE 10 MG ON CAR DRIVING PERFORMANCE [J].
BROOKHUIS, KA ;
DEVRIES, G ;
DEWAARD, D .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1993, 36 (01) :67-70
[4]   PERFORMANCE STUDIES WITH ANTIHISTAMINES [J].
CLARKE, CH ;
NICHOLSON, AN .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1978, 6 (01) :31-35
[5]  
Day J. H., 1996, Journal of Allergy and Clinical Immunology, V97, P434, DOI 10.1016/S0091-6749(96)81225-5
[6]   H-1-RECEPTOR ANTAGONISTS - COMPARATIVE TOLERABILITY AND SAFETY [J].
ESTELLE, F ;
SIMONS, R .
DRUG SAFETY, 1994, 10 (05) :350-380
[7]  
*HOECHST MAR ROUSS, 1995, FEX HYDR MDL 16455A
[8]   A CRITICAL TRACKING TASK FOR MANUAL CONTROL RESEARCH [J].
JEX, HR ;
MCDONNEL.JD ;
PHATAK, AV .
IEEE TRANSACTIONS ON HUMAN FACTORS IN ELECTRONICS, 1966, HFE7 (04) :138-+
[9]   STIMULANT-DRUGS AND VIGILANCE PERFORMANCE - A REVIEW [J].
KOELEGA, HS .
PSYCHOPHARMACOLOGY, 1993, 111 (01) :1-16
[10]  
LING KHJ, 1995, DRUG METAB DISPOS, V23, P631